SG Americas Securities LLC Purchases 17,577 Shares of MacroGenics, Inc. (NASDAQ:MGNX)

SG Americas Securities LLC increased its position in MacroGenics, Inc. (NASDAQ:MGNX) by 104.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,399 shares of the biopharmaceutical company’s stock after acquiring an additional 17,577 shares during the quarter. SG Americas Securities LLC owned about 0.05% of MacroGenics worth $112,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. XTX Topco Ltd acquired a new stake in MacroGenics in the 3rd quarter worth $37,000. China Universal Asset Management Co. Ltd. grew its position in MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock worth $40,000 after purchasing an additional 4,707 shares during the last quarter. Sanders Morris Harris LLC acquired a new stake in MacroGenics in the 4th quarter worth $40,000. XML Financial LLC grew its position in MacroGenics by 66.0% in the 3rd quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 7,000 shares during the last quarter. Finally, Intech Investment Management LLC acquired a new stake in MacroGenics in the 3rd quarter worth $68,000. 96.89% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Price Performance

Shares of MGNX opened at $2.40 on Thursday. The company has a market capitalization of $150.62 million, a P/E ratio of -1.52 and a beta of 2.02. MacroGenics, Inc. has a one year low of $2.34 and a one year high of $21.88. The business’s 50 day simple moving average is $3.14 and its 200-day simple moving average is $3.45.

Analysts Set New Price Targets

Several research firms have issued reports on MGNX. StockNews.com upgraded shares of MacroGenics from a “sell” rating to a “buy” rating in a research report on Sunday, November 10th. JMP Securities lowered shares of MacroGenics from an “outperform” rating to a “market perform” rating in a research report on Thursday, November 7th. Finally, HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price objective on shares of MacroGenics in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $7.63.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.